STANDARD_NAME	HARALAMBIEVA_PBMC_DRYVAX_AGE_18_40YO_STIMULATED_VS_UNSTIMULATED_9_TO_34MO_UP
SYSTEMATIC_NAME	M41189
COLLECTION	C7:VAX
MSIGDB_URL	https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_DRYVAX_AGE_18_40YO_STIMULATED_VS_UNSTIMULATED_9_TO_34MO_UP
NAMESPACE	HUMAN_GENE_SYMBOL
DESCRIPTION_BRIEF	Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in adults (18-40) after exposure to Dryvax , time point 9 to 34M. Comment: Original exposure within previous 4 years
DESCRIPTION_FULL	BACKGROUND: The mechanisms underlying smallpox vaccine-induced variations in immune responses are not well understood, but are of considerable interest to a deeper understanding of poxvirus immunity and correlates of protection. METHODS: We assessed transcriptional messenger RNA expression changes in 197 recipients of primary smallpox vaccination representing the extremes of humoral and cellular immune responses. RESULTS: The 20 most significant differentially expressed genes include a tumor necrosis factor-receptor superfamily member, an interferon (IFN) gene, a chemokine gene, zinc finger protein genes, nuclear factors, and histones (P <= 1.06E(-20), q <= 2.64E(-17)). A pathway analysis identified 4 enriched pathways with cytokine production by the T-helper 17 subset of CD4+ T cells being the most significant pathway (P = 3.42E(-05)). Two pathways (antiviral actions of IFNs, P = 8.95E(-05); and IFN-alpha/beta signaling pathway, P = 2.92E(-04)), integral to innate immunity, were enriched when comparing high with low antibody responders (false discovery rate, < 0.05). Genes related to immune function and transcription (TLR8, P =.0002; DAPP1, P =.0003; LAMP3, P = 9.96E(-05); NR4A2, P <= .0002; EGR3, P = 4.52E(-05)), and other genes with a possible impact on immunity (LNPEP, P = 3.72E(-05); CAPRIN1, P =.0001; XRN1, P =.0001), were found to be expressed differentially in high versus low antibody responders. CONCLUSION: We identified novel and known immunity-related genes and pathways that may account for differences in immune response to smallpox vaccination.
PMID	22949304
GEOID	
AUTHORS	Haralambieva IH,Oberg AL,Dhiman N,Ovsyannikova IG,Kennedy RB,Grill DE,Jacobson RM,Poland GA
CONTRIBUTOR	HIPC SIGNATURES
CONTRIBUTOR_ORG	NIAID/HIPC SIGNATURES
EXACT_SOURCE	Table 2
FILTERED_BY_SIMILARITY	
EXTERNAL_NAMES_FOR_SIMILAR_TERMS	
EXTERNAL_DETAILS_URL	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475634/table/JIS546TB2/
SOURCE_MEMBERS	CCAR2,CD160,FAM71B,H4C5,HERC5,IFNA1,IKZF1,IKZF2,NEXN,NFE2L3,NR4A2,POLR2C,RSRC1,SOBP,TNFRSF10D,TNK2,XCL1
GENE_SYMBOLS	CCAR2,CD160,GARIN3,H4C5,HERC5,IFNA1,IKZF1,IKZF2,NEXN,NFE2L3,NR4A2,POLR2C,RSRC1,SOBP,TNFRSF10D,TNK2,XCL1
FOUNDER_NAMES